These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 23410207)
1. Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions. Mullier F; Bailly N; Chatelain C; Chatelain B; Dogné JM J Thromb Haemost; 2013 Apr; 11(4):693-6. PubMed ID: 23410207 [No Abstract] [Full Text] [Related]
2. Is a decrease of microparticles related to improvement of hemostasis after FVIII injection in hemophilia A patients treated on demand? Mobarrez F; Mikovic D; Antovic A; Antovic JP J Thromb Haemost; 2013 Apr; 11(4):697-703. PubMed ID: 23231463 [TBL] [Abstract][Full Text] [Related]
3. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use. Hugenholtz GC; Luddington R; Baglin T Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112 [No Abstract] [Full Text] [Related]
4. Coronary artery bypass surgery in a patient with Haemophilia A: a case report. Menard CE; Zawadski D; Singal RK; Rimmer E; Houston DS; Houston BL; Zarychanski R Haemophilia; 2016 Jan; 22(1):e76-9. PubMed ID: 26635300 [No Abstract] [Full Text] [Related]
5. Does the intensity and quality of treatment and not only the factor VIII level influence global hemostasis in patients with hemophilia A? Berndtsson M; Zetterberg E; Holmström M; Mahmoud Hourani Soutari N; Mikovic D; Elezovic I; Antovic JP Thromb Res; 2016 Aug; 144():133-5. PubMed ID: 27331346 [No Abstract] [Full Text] [Related]
6. Measurement of factor VIII pharmacokinetics in routine clinical practice. Björkman S; Collins P; J Thromb Haemost; 2013 Jan; 11(1):180-2. PubMed ID: 23279622 [No Abstract] [Full Text] [Related]
7. One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. Lippi G; Franchini M; Favaloro EJ Blood Coagul Fibrinolysis; 2009 Jan; 20(1):1-3. PubMed ID: 20527719 [No Abstract] [Full Text] [Related]
8. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence. Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655 [TBL] [Abstract][Full Text] [Related]
9. Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone. Aguila S; O'Donnell JS J Thromb Haemost; 2019 Mar; 17(3):426-428. PubMed ID: 30652400 [No Abstract] [Full Text] [Related]
10. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389 [TBL] [Abstract][Full Text] [Related]
11. Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Freedman J; Mody M; Lazarus AH; Dewar L; Song S; Blanchette VS; Garvey MB; Ofosu FA Am J Hematol; 2002 Mar; 69(3):192-9. PubMed ID: 11891806 [TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969 [TBL] [Abstract][Full Text] [Related]
13. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene. Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198 [TBL] [Abstract][Full Text] [Related]
14. Letter: Rising factor VIII inhibitor titers after Konyne factor IX complex. Kasper CK; Feinstein DI N Engl J Med; 1976 Aug; 295(9):505-6. PubMed ID: 59902 [No Abstract] [Full Text] [Related]
15. Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Yoshioka A; Nishio K; Shima M Haemostasis; 1996; 26 Suppl 1():139-42. PubMed ID: 8904189 [TBL] [Abstract][Full Text] [Related]
16. [Chronic liver dysfunction in patients with hemophilia A. Effect of introduction of factor VIII concentrate]. Kojima S; Tonouchi T; Ikegaya M; Mimaya J Rinsho Ketsueki; 1984 Jan; 25(1):31-6. PubMed ID: 6431147 [No Abstract] [Full Text] [Related]
17. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice. Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350 [TBL] [Abstract][Full Text] [Related]